Analysts expect Assembly Biosciences Inc (NASDAQ:ASMB) to announce earnings of ($1.02) per share for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for Assembly Biosciences’ earnings, with estimates ranging from ($1.15) to ($0.94). Assembly Biosciences reported earnings per share of ($0.71) in the same quarter last year, which suggests a negative year-over-year growth rate of 43.7%. The firm is scheduled to report its next quarterly earnings results on Wednesday, November 7th.

On average, analysts expect that Assembly Biosciences will report full year earnings of ($4.12) per share for the current fiscal year, with EPS estimates ranging from ($4.51) to ($3.76). For the next financial year, analysts expect that the firm will report earnings of ($3.99) per share, with EPS estimates ranging from ($5.35) to ($2.27). Zacks’ earnings per share calculations are an average based on a survey of research analysts that that provide coverage for Assembly Biosciences.

Assembly Biosciences (NASDAQ:ASMB) last released its quarterly earnings results on Wednesday, August 8th. The biopharmaceutical company reported ($1.30) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.88) by ($0.42). Assembly Biosciences had a negative net margin of 457.20% and a negative return on equity of 66.34%. The company had revenue of $3.22 million for the quarter, compared to analysts’ expectations of $3.30 million.

Several analysts recently weighed in on ASMB shares. Robert W. Baird started coverage on Assembly Biosciences in a report on Wednesday, August 8th. They set an “outperform” rating and a $74.00 price target on the stock. Zacks Investment Research upgraded Assembly Biosciences from a “sell” rating to a “hold” rating in a report on Tuesday, July 10th. Finally, BidaskClub lowered Assembly Biosciences from a “sell” rating to a “strong sell” rating in a research note on Friday, July 13th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company. Assembly Biosciences presently has a consensus rating of “Hold” and a consensus price target of $63.20.

NASDAQ:ASMB traded down $0.33 during midday trading on Friday, hitting $36.13. 1,522 shares of the company traded hands, compared to its average volume of 183,742. Assembly Biosciences has a 12-month low of $27.00 and a 12-month high of $67.36. The firm has a market capitalization of $950.68 million, a PE ratio of -14.83 and a beta of 0.82.

In other news, VP Uri A. Lopatin sold 15,204 shares of the firm’s stock in a transaction on Wednesday, September 5th. The stock was sold at an average price of $40.09, for a total transaction of $609,528.36. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director William R. Ringo sold 1,000 shares of the firm’s stock in a transaction on Monday, July 2nd. The shares were sold at an average price of $38.50, for a total value of $38,500.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 31,744 shares of company stock worth $1,271,027. Insiders own 18.20% of the company’s stock.

Several institutional investors have recently made changes to their positions in ASMB. Bank of Montreal Can purchased a new position in shares of Assembly Biosciences during the second quarter valued at $145,000. Quantbot Technologies LP purchased a new position in shares of Assembly Biosciences during the first quarter valued at $154,000. Jane Street Group LLC purchased a new position in shares of Assembly Biosciences during the first quarter valued at $204,000. MetLife Investment Advisors LLC purchased a new position in shares of Assembly Biosciences during the second quarter valued at $282,000. Finally, Quantitative Systematic Strategies LLC purchased a new position in shares of Assembly Biosciences during the second quarter valued at $348,000. Hedge funds and other institutional investors own 65.21% of the company’s stock.

About Assembly Biosciences

Assembly Biosciences, Inc operates as a clinical stage biotechnology company. It develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome in the United States.

Featured Article: Return on Investment (ROI) Defined, Explained

Get a free copy of the Zacks research report on Assembly Biosciences (ASMB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Assembly Biosciences (NASDAQ:ASMB)

Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.